Haemonetics Corporation (HAE)
| Market Cap | 3.38B -2.3% |
| Revenue (ttm) | 1.33B -2.0% |
| Net Income | 97.31M -42.0% |
| EPS | 2.05 -38.1% |
| Shares Out | 45.45M |
| PE Ratio | 36.32 |
| Forward PE | 14.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 244,787 |
| Open | 74.00 |
| Previous Close | 74.88 |
| Day's Range | 73.71 - 74.90 |
| 52-Week Range | 47.32 - 87.32 |
| Beta | 0.52 |
| Analysts | Buy |
| Price Target | 85.20 (+14.43%) |
| Earnings Date | Aug 6, 2026 |
About HAE
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management syst... [Read more]
Financial Performance
In fiscal year 2026, Haemonetics's revenue was $1.33 billion, a decrease of -1.97% compared to the previous year's $1.36 billion. Earnings were $97.31 million, a decrease of -41.97%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for HAE stock is "Buy." The 12-month stock price target is $85.2, which is an increase of 14.43% from the latest price.
News
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026
BOSTON, July 8, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, Augus...
Citi adds ‘downside 90-day catalyst watch’ on Haemonetics
Citi analyst Joanne Wuensch is adding a “downside 90-day catalyst watch” on Haemonetics (HAE), raised the firm’s price target on shares to $79 from $70 and keeps a Neutral rating.
Haemonetics management to meet virtually with BTIG
Virtual Meeting to be held on June 24 hosted by BTIG.
Haemonetics price target raised to $85 from $70 at Mizuho
Mizuho raised the firm’s price target on Haemonetics (HAE) to $85 from $70 and keeps an Outperform rating on the shares. The firm attributes the recent rally in the shares…
Pharvaris Announces Annual General Meeting of Shareholders
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet nee...
Haemonetics Proxy statement: Proxy filing
Haemonetics filed a proxy statement on June 9, 2026, providing details for shareholder voting and corporate governance matters.
Haemonetics Proxy statement: Proxy filing
Haemonetics filed a proxy statement on June 9, 2026, providing details for shareholder voting and corporate governance matters.
Haemonetics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management highlighted strong execution on a four-year transformation plan, surpassing growth and earnings targets, and set conservative FY 2027 guidance of 3%-6% organic growth. Key drivers include innovation, share gains, and operational leverage, with upside potential from faster technology adoption and market stabilization.
Haemonetics Updates Financial Reporting Segments
BOSTON, June 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today ann...
Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference
BOSTON, June 2, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Goldman Sachs 47th Ann...
Haemonetics price target raised to $70 from $64 at Citi
Citi raised the firm’s price target on Haemonetics (HAE) to $70 from $64 and keeps a Neutral rating on the shares. The firm updated models in the medical technology space…
Haemonetics upgraded to Buy at BofA on upside to guidance
As previously reported, BofA analyst Travis Steed upgraded Haemonetics (HAE) to Buy from Neutral with a price target of $80, up from $72. The firm, which thinks that it seems…
Haemonetics upgraded to Buy from Neutral at BofA
BofA upgraded Haemonetics (HAE) to Buy from Neutral with a price target of $80, up from $72.
Haemonetics Transcript: Bank of America Global Healthcare Conference 2026
Management highlighted robust revenue and margin growth, driven by core products and innovation in plasma and hospital businesses. Vascular closure is rebounding, and blood management technologies are accelerating. The company is focused on organic growth, margin expansion, and capital returns.
Haemonetics price target lowered to $89 from $94 at Barrington
Barrington lowered the firm’s price target on Haemonetics (HAE) to $89 from $94 and keeps an Outperform rating on the shares citing somewhat lower profitability expectations for FY27 based on…
Haemonetics price target lowered to $67 from $72 at Baird
Baird analyst David Rescott lowered the firm’s price target on Haemonetics (HAE) to $67 from $72 and keeps an Outperform rating on the shares. The firm updated its model following…
Haemonetics price target lowered to $62 from $74 at JPMorgan
JPMorgan lowered the firm’s price target on Haemonetics (HAE) to $62 from $74 and keeps a Neutral rating on the shares.
Haemonetics Earnings Call Transcript: Q4 2026
Q4 and full-year results showed strong organic growth, margin expansion, and robust free cash flow, driven by Plasma and TEG platforms. Fiscal 2027 guidance projects continued revenue and margin growth, with innovation and portfolio transformation supporting future performance.
Haemonetics Earnings release: Q4 2026
Haemonetics released its Q4 2026 earnings on May 7, 2026, summarizing the period's financial results.
Haemonetics Slides: Q4 2026
Haemonetics has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 7, 2026.
Haemonetics Annual report: Q4 2026
Haemonetics has published its Q4 2026 annual report on May 7, 2026.
Haemonetics Annual report: Q4 2026
Haemonetics has published its Q4 2026 annual report on May 7, 2026.
Haemonetics reports Q4 adjusted EPS $1.29, consensus $1.27
Reports Q4 revenue $346.35M, consensus $336.86M. Chris Simon, Haemonetics (HAE)’ CEO, stated: “Strong fourth quarter performance was largely driven by our core platforms, with outperformance in Plasma...
Haemonetics sees FY27 adjusted EPS up 4%-7%
Sees FY27 revenue up 4%-7%. Sees FY27 free cash flow conversion 80%.
Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
Financial release and supplemental presentation accessible online BOSTON, May 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter fiscal...